HR Execs on the Move

EnviroLogix

www.envirologix.com

 
Pioneering GMO and mycotoxin testing technologies and pushing boundaries forward in life science labs, grain markets and the global food supply chain.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.envirologix.com
  • 500, Riverside Industrial Parkway
    Portland, ME USA 04103
  • Phone: 866.408.4597

Executives

Name Title Contact Details
Terry Goddard
Vice President Of Product Development Profile

Similar Companies

ProteomTech Inc

ProteomTech Inc is a Costa Mesa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioNJ

BioNJ is a Trenton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AOBiome

AOBiome LLC is developing first-in-class topical biologics for the treatment of inflammatory skin conditions. We have developed extensive scientific and manufacturing expertise on the use of beneficial ammonia-oxidizing bacteria (AOB). AOB are naturally occurring bacteria that metabolize the ammonia found in sweat, creating both nitrite and nitric oxide, with both anti-inflammatory and anti-infective properties. The therapeutic potential of nitrite and nitric oxide are widely recognized, although as yet, largely unrealized as delivery, let alone targeted delivery is extremely difficult. The company`s proprietary AOB offers the potential of a first-in-class natural delivery system for nitrite and nitric oxide.

Goldfinch Bio

Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for kidney disease. Just as the goldfinch was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for patients with kidney disease. Goldfinch is integrating breakthroughs in kidney genetics and biology to identify new therapeutic targets and advance first-in-class drug candidates to treat patients with kidney disease. Our Product Engine will industrialize the integration of genetics and kidney biology and confer a differentiated ability to identify, validate, and pursue novel therapeutic targets to treat progressive kidney disease. At Goldfinch, we`re pioneering a new approach to discover and develop therapeutics that target the molecular basis of kidney disease. We`re looking for teammates who relish the challenge, and are compelled to leave a positive mark on the lives of colleagues and patients alike.

Verenium Corporation

Verenium Corporation (Verenium), possesses a portfolio of specialty enzyme products and is developing technical and operational capabilities designed to enable the production of low-cost, biomass-derived sugars for a number of industrial applications,